Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
The New England Journal of Medicine
|
October 17, 2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Orthopaedic Journal of Sports Medicine
|
June 8, 2017
Outcome of Expedited Rotator Cuff Surgery in Injured Workers: Determinants of Successful Recovery
Helen Razmjou, Dragana Boljanovic, Sandra Lincoln, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
The New England Journal of Medicine
|
September 13, 2024
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng, David R Spigel, Byoung Chul Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Nature
|
October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature
|
February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
The New England Journal of Medicine
|
October 17, 2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Orthopaedic Journal of Sports Medicine
|
June 8, 2017
Outcome of Expedited Rotator Cuff Surgery in Injured Workers: Determinants of Successful Recovery
Helen Razmjou, Dragana Boljanovic, Sandra Lincoln, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
The New England Journal of Medicine
|
September 13, 2024
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng, David R Spigel, Byoung Chul Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Nature
|
October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature
|
February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Page
of 6